Iovance Biotherapeutics

Iovance Biotherapeutics is a California-based biotech firm pioneering tumor-infiltrating lymphocyte (TIL) therapies for cancer treatment.

Their flagship product, Lifileucel (marketed as Amtagvi), received FDA approval in 2024 for treating advanced melanoma. The company aims to expand its innovative treatments globally, focusing on personalized immunotherapies to combat solid tumors.​

Address: Suite 400, 825 Industrial Road, San Carlos, California, 94070

Phone: (650)260-7120